Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome

Lupus ◽  
2018 ◽  
Vol 28 (1) ◽  
pp. 123-128 ◽  
Author(s):  
M R Ugolini-Lopes ◽  
L P S Santos ◽  
C Stagnaro ◽  
L P C Seguro ◽  
M Mosca ◽  
...  

Background/Purpose Lupus nephritis (LN) usually develops within the first years of systemic lupus erythematosus (SLE) onset and rarely after that. There are scarce studies comparing early- versus late-onset nephritis (before versus after five years of SLE diagnosis). The aim of this study was to compare the severity and long-term outcome (after 7 years) in these two, late-onset and early-onset, nephritis groups. Methods This study included 93 patients from rheumatology tertiary centers from Brazil and Italy, all of them with biopsy-proven LN with > 7 years follow-up. Patients were divided in two groups: early-onset nephritis ( n = 75) and late-onset nephritis ( n = 18). Clinical and laboratorial data were obtained using a standardized electronic chart database protocol carried out at 1–6 months interval and established in 2000. Patients >50 years or with concomitant autoimmune diseases were excluded. Variables evaluated at the LN presentation were Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), creatinine, albumin, anti-DNA positivity and nephritis class. Variables evaluated at the long-term outcome (after 7 years) were Systemic Lupus International Collaborating Clinics Damage Index (SDI), creatinine, dialysis and mortality. Results The average time of LN presentation was 10.94 ± 3.73 years for the late-onset and 1.20 ± 1.60 years for the early-onset group. Their similar nephritis duration (12.44 ± 3.2 versus 13.28 ± 4.03 years, p = 0.41) and comparable mean ages (49.17 ± 9.9 versus 44.11 ± 10.8 years old, p = 0.06) allow a more accurate comparison. Regarding severity, late-onset was similar to early-onset group: SLEDAI (8 (range: 6–22) versus 12 (range: 2–24), p = 0.47), creatinine (1.36 ± 0.94 versus 1.36 ± 1.13 mg/dl, p = 0.99); albumin (2.84 ± 0.65 versus 2.59 ± 0.84 mg/dl, p = 0.30); proteinuria (3.77 ± 2.18 versus 5.01 ± 4.51 g/vol, p = 0.26); proliferative nephritis (44% ( n = 8) versus 60% ( n = 45), p = 0.23). There was also no difference in the long-term outcomes between groups: SDI (1 (range: 0–5) versus 0.5 (range: 0–5), p = 0.27); creatinine (2.04 ± 2.38 versus 1.69 ± 2.26 mg/dl, p = 0.56); dialysis (22% ( n = 4) versus 13% ( n = 10), p = 0.46) and mortality (0% ( n = 0) versus 12% ( n = 9), p = 0.19). Conclusion This study provides novel evidence of comparable long-term outcomes between late-onset and early-onset nephritis, which is most likely explained by the observation that at presentation, the clinical, laboratorial and histological features of late-onset and early-onset nephritis are similar. This suggests that there should be no distinct treatment targets and therapeutic interventions for the late- and early-onset groups.

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Simone Fargetti ◽  
Michelle R. Ugolini-Lopes ◽  
Sandra G. Pasoto ◽  
Luciana P. C. Seguro ◽  
Samuel K. Shinjo ◽  
...  

Medicine ◽  
2006 ◽  
Vol 85 (3) ◽  
pp. 169-182 ◽  
Author(s):  
Olivier Lambotte ◽  
Mehdi Khellaf ◽  
Hicham Harmouche ◽  
Brigitte Bader-Meunier ◽  
Véronique Manceron ◽  
...  

1998 ◽  
Vol 66 (8) ◽  
pp. 1000-1003 ◽  
Author(s):  
Philippe Grimbert ◽  
Jerome Frappier ◽  
Jeanine Bedrossian ◽  
Christophe Legendre ◽  
Corinne Antoine ◽  
...  

2012 ◽  
Vol 41 (5) ◽  
pp. 642-651 ◽  
Author(s):  
Gabriella Moroni ◽  
Silvana Quaglini ◽  
Luciana Gravellone ◽  
Beniamina Gallelli ◽  
Antonio Leoni ◽  
...  

Lupus ◽  
2020 ◽  
Vol 29 (9) ◽  
pp. 1115-1120 ◽  
Author(s):  
Byung-Woo Yoo ◽  
Sang-Won Lee ◽  
Jason Jungsik Song ◽  
Yong-Beom Park ◽  
Seung Min Jung

Objective Treatment of Libman–Sacks (LS) endocarditis in patients with systemic lupus erythematosus (SLE) is challenging due to the lack of data. This study aimed to identify the clinical characteristics of SLE patients and LS endocarditis, and to investigate the treatment and prognosis of LS endocarditis. Methods Of all the patients with SLE who underwent echocardiography between 2010 and 2019, 11 and 29 patients with and without LS endocarditis, respectively, were included. We compared the inflammatory and thrombotic profiles between patients with and without LS endocarditis, and investigated the treatment and long-term outcome of LS endocarditis. Results No significant differences were observed in disease activity, clinical characteristics and inflammatory marker levels between patients with and without LS endocarditis. Patients with LS endocarditis had a significantly higher prevalence of antiphospholipid antibody (aPL) but a lower prevalence of SLE-specific antibody. Triple positivity of aPL was found in 72.7% and 13.8% of patients with and without LS endocarditis, respectively. Of 11 patients with LS endocarditis, six patients received anticoagulation therapy, and five patients received augmented immunosuppressive therapies. One patient who did not receive anticoagulation therapy developed cerebral infarction. Nine (82%) patients with LS endocarditis were classified as having antiphospholipid syndrome (APS). Despite the residual vegetation and valve dysfunction, surgical intervention was not required during the follow-up period of 56.8 months. Conclusion A significant correlation was observed between APS and LS endocarditis. Anticoagulation therapy should be considered to prevent thromboembolic complications in SLE patients with LS endocarditis.


Sign in / Sign up

Export Citation Format

Share Document